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Background & Aims: To describe the burden on inpatient hospital resources over time from 
patients diagnosed with hepatitis C virus (HCV) infection and who have reached the 
decompensated stage of cirrhosis (DC), as existing estimates of hospital stay in these patients are 
limited. 
Methods: A retrospective longitudinal dataset was formed via record-linkage between the national 
HCV diagnosis database and inpatient/daycase hospitalisation and death registers in Scotland. The 
study population consisted of HCV-diagnosed patients with a first DC admission in 1996-2013, 
with follow-up available until 31 May 2014. We investigated and quantified the mean cumulative 
length of hospital stay, distributions over discharge diagnosis categories, and trends in admission 
rates. 
Results: Among our study population (n=1543), we identified 10,179 admissions with any 
diagnosis post-first DC admission. Between 1996 and 2013 there was a 16-fold rise in annual total 
admissions (from 112 to 1791) and an 11-fold rise in hospital stay (719 to 8045). When restricting 
minimum possible follow-up to two years, DC patients (n=1312) had an overall admission rate of 
7.3 per person-year, and spent on average 43 days (26 days during first 6 months) in hospital; for 
all liver-related, liver-related other than HCC/DC, and non-liver related only admissions, this was 
39, 14, and 5 days, respectively. 
Conclusions: HCV-infected DC patients impose a considerable inpatient hospital burden, mostly 
from DC- and other liver-related admissions, but also from admissions associated with non-liver 
co-morbidities. Estimates will be useful for monitoring the impact of prevention and treatment, 
and for computing the cost-effectiveness of new therapies. 
Word count: 250 
3 
Keywords: Hospital stay; Decompensated cirrhosis; Hepatitis C virus; Scotland 
 
KEYPOINTS 
 Patients with HCV who have progressed to decompensated liver disease represent a 
substantial burden on health care resources. 
 Up-to-date figures on resource use, such as hospital stay, based on a large patient sample, are 
required to inform cost-effectiveness models of current DAA treatments. 
 We provide estimates of the morbidity burden in HCV-infected DC patients, for both liver 
disease and also non-liver co-morbidities and behaviours, which contributed notably to the 
inpatient hospital burden. 
 These findings constitute a baseline against which any improvements in the care and 




Chronic infection with the hepatitis C virus (HCV) can lead to the generally asymptomatic phase 
of compensated cirrhosis, from which progression to the severe, life-threatening stage of 
decompensated cirrhosis (DC) occurs with a 10-year cumulative incidence of 42%.1 In the pre-
direct acting antiviral (DAA) therapy era, the annual risk of mortality following DC without liver 
transplantation was very high.2 A recent Scottish record-linkage study reported a 5-year 
cumulative risk of mortality of 70% after first inpatient hospital admission for DC, with no 
evidence for any improvement in mortality risk over the 20-year study period 1994–2013.3 Upon 
expansion of DAA treatment to DC-stage patients,4 promising reported viral clearance rates5,6 may 
translate to improved survival, but data from long-term follow-up studies are not yet available. 
 
Mortality findings may not generalise to temporal trends in the morbidity burden. Because of – in 
some cases, extensive – co-morbidities among HCV-infected persons (for instance, mental health 
disorders,7 or conditions related to lifestyle behaviours such as problem alcohol/drug use;8 or 
chronic diseases prevalent in older persons: cardiovascular and respiratory impairments; diabetes, 
cancer; e.g., Ref. 9), it is important to quantify the health-care associated burden in this patient 
population attributable to both liver- and non-liver related causes.  
 
The financial burden due to patient care and management once chronic HCV patients progress to 
the DC stage is recognised as considerable. For instance, economic evaluations carried out for the 
USA birth cohort screening initiative adopted annualised direct costs for DC patient care in the 
range of US$11,000 to $28,000.10-12 In the European setting, annual hospitalisation costs of 8000-




In one of the few UK studies to quantify the length of hospital stay in HCV-infected patients 
according to disease stage,15 21.1 days was reported as the mean annualised length of stay in 
hospital for DC patients (without HCC), with 22.6 days per year for HCC patients (with or without 
DC). The authors translate these figures to a mean annual total cost of £9,120 per year (in 2002/03 
prices), of which the principal cost component was inpatient hospital stay, accounting for more 
than 70% of the total cost. These values are based on 40 DC and 20 HCC patients taking part in an 
observational costing substudy of the UK Mild Hepatitis C trial,15,16 and the associated cost-
effectiveness analysis for the National Institute for Health and Care Excellence depended on these 
burden estimates. Although estimates from the MILD trial are derived from a small study 
population over a two-year recruitment period more than 15 years ago, subsequent economic 
analyses both in and outwith the UK still use these figures (e.g., Refs. 17,18). It is therefore prudent 
to derive updated estimates using a larger, national sample of patients, and to consider the excess 
hospitalisation that may not be directly related to HCV liver disease, but nonetheless occurs in 
these patients. Updated hospital stay data will also serve a vital role for assessing the impact of 
interferon-free antiviral therapy in preventing DC and its associated morbidity. 
 
The current study follows-up a large nationwide cohort of patients admitted to hospital with DC, 
to generate real-world estimates of morbidity burden in this population. Our primary goal was to 
quantify the extent of inpatient hospital usage among DC patients by calculating the mean 
cumulative length of stay for all admissions and for liver-related and non-liver related admission 
categories separately. As secondary objectives we analysed temporal trends in admission rates, 
and investigated the distribution of admissions according to severity over the follow-up period. 
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MATERIALS AND METHODS 
Data sources and record-linkage 
Linkage of three national data sources was carried out by Information Services Division (a division 
of NHS National Services Scotland) using probabilistic record-linkage techniques.19 This linked 
dataset was anonymized prior to transfer to HPS for analysis. Data linkages were approved by the 
Privacy Advisory Committee, which oversees confidentiality issues involving data held on NHS 
Scotland patients. Further ethical approval and informed consent were not required for this 
database study. 
 
The linked dataset consisted of: (i) a database, maintained by Health Protection Scotland, of all 
persons in Scotland who have been diagnosed HCV positive since testing commenced in 1991 
(including stored serum back to 1985);20 laboratory detection of hepatitis C antibody is an inclusion 
criterion. As of 31 December 2013, the HCV Diagnosis database contained records for 35,474 
persons.21 It is estimated that approximately 55% of the current HCV-infected Scottish population 
have been diagnosed.22 Source (ii) is the Scottish Morbidity Records, an episode-based patient 
record held by Information Services Division of all general acute inpatient and day-case hospital 
discharges. Discharge diagnoses use International Classification of Diseases (ICD) Tenth Revision 
for hospital discharges in the period 1996-2014. Data source (iii) is the national death registry held 
by the National Records of Scotland (NRS). Underlying and contributing causes of death are coded 
using ICD–9 and ICD–10 for deaths in 1996–1999 and 2000–2014, respectively. We had deaths and 
hospitalisation data available until 31 May 2014, and began our analysis in 1 January 1996, the year 
when ICD-10 was implemented in the Scottish Morbidity Records. 
 
A further linkage between the HCV Diagnosis and the Scottish Hepatitis C Clinical Database was 
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conducted at HPS to determine the HCV RNA status at date of index DC admission for those 
patients who had previously been successfully treated with antiviral therapy (see Ref. 23 for 
further details). This database, also held at Health Protection Scotland, contains data on all aspects 
of HCV care and patient management and is deployed at specialist HCV treatment centres within 
Scotland. 
 
Study population  
The study population consisted of all HCV-diagnosed patients with a first inpatient/day-case 
admission for DC in Scotland over the period 1996–2013. Patients whose first DC admission 
occurred more than one year preceding HCV diagnosis were excluded, in an attempt to reduce 
potential bias due to DC arising from a different aetiology. HCV RNA status was not restricted to 
PCR-positive in the principal analysis, but in sensitivity analyses we stratify by RNA status. 
 
An admission for DC was defined according to the presence of a relevant ICD-10 code(s) in either 
the main or five supplementary diagnosis fields of the episode record. DC discharge diagnosis 
codes were categorised into: hepatic failure (aggregating the diagnosis codes comprising chronic 
hepatic failure, alcoholic hepatic failure, and hepatorenal syndrome), ascites, and bleeding 
oesophageal varices (for ICD-10 codes comprising these definitions see Supporting Information, 
Table S1). The selected diagnosis codes have been used in previous DC research.3,24 We use the 
terms admission and discharge equivalently, assuming that discharge diagnoses encode the reason 
for admission. Successive inpatient episodes without release from hospital, and/or transfers 
between specialty or consultant, with identical sets of discharge diagnoses, are counted as a single 
admission. Episodes with an identical date of admission and discharge (most often day-cases) 
contributed 0.5 days to measures of total hospital stay. 
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Patient characteristics and exposure variables 
Demographic and behavioural factors (sex, age, risk group for acquiring HCV infection, history of 
an alcohol-related hospitalisation prior to first DC admission), HCV-related factors (RNA status at 
first DC admission, operationalised as the most recent PCR test result: positive, negative, or not 
known; relevant for sensitivity analysis), and liver disease-related variables (prevalence of cirrhotic 
complications – based on discharge diagnosis codes – at index DC admission, history of HCC 
admission(s) prior to first DC admission), and mortality data were extracted and tabulated. 
 
Data analysis  
Analysis goals. Our specific aims were to: (i) estimate the burden of hospital usage by DC patients 
as mean cumulative length of stay, both overall and stratified by admission diagnosis category, 
and determine the factors associated with cumulative length of stay; (ii) describe the inpatient 
hospital burden according to time since first DC admission; (iii) investigate temporal trends in the 
annual total admissions and admission rate, and estimate the associations between admission rate 
and patient factors; and (iv) summarise the distribution over severity-ranked categories of hospital 
admission and compute mean length of stay as a function of follow-up time, distinguishing liver- 
and non-liver related admissions. 
 
Outcome measures. From the DC patients´ entire hospital record including and subsequent to the 
first DC admission, the total number of inpatient admissions, admission rate, and total stay in 
hospital were calculated for each year of the study period, and the mean cumulative stay per 
patient was calculated according to various follow-up definitions (see below). We report all-cause 
admissions (i.e., with any diagnosis), and distinguish liver-related and non-liver-related 
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admissions: (a) liver-related, consisting of: HCC, hepatic failure (chronic liver failure, hepatorenal 
syndrome), ascites/bleeding varices, other liver-related admissions (which includes alcohol-related 
diagnosis codes; see Table S1); (b) non-liver related admissions – these consisted of all other 
admissions in which none of the above codes were indicated in any of the five discharge diagnosis 
fields. The subcategories of liver-related admissions were defined hierarchically according to 
severity (itself defined according to short-term mortality risk); i.e., if an HCC code occurred in any 
diagnosis field, then the episode was categorised as HCC. However, if no HCC code, but a hepatic 
failure code occurred in any diagnosis field, then the episode was classified as hepatic failure. 
Classification of episodes into categories lower in the hierarchy was conducted analogously; i.e., if 
no liver-related code occurred in any diagnosis field, the episode was classified as a non-liver 
related admission. 
 
Within the category ‘non-liver related’, four subcategories were defined based on frequency of 
occurrence: circulatory and respiratory, digestive system other than liver, injuries and poisonings, and 
other non-liver (Supporting Information, Table S1). Each non-liver related episode was classified 
using an analogous hierarchical procedure. 
 
Follow-up. Two definitions of follow-up were used, specific to the type of analysis. In the first (for 
producing Table 2), the study population was defined as those HCV-diagnosed persons with a 
first DC admission between 1996 and 31 May 2012; this ensured a minimum potential observation 
period of two years for all patients. Follow-up was censored at (i) 31 May 2014, regardless of 
patients’ date of first DC admission, and also according to three censoring thresholds: (ii) 2 years, 
(iii) 1 year, and (iv) 6 months following index admission.  
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In the second follow-up definition, in which admission rate across triennium of the study period is 
investigated (Table 1b), follow-up was defined to begin at the date of the first DC hospital 
admission, and to end at five months following the end of the triennium in which the first DC 
admission fell. For example, for the last triennium (2011–2013), follow-up was censored at 31 May 
2014; similarly, follow-up for the triennium 2008–2010 was censored at 31 May 2011. This was to 
ensure comparability in admission rates across period of first DC admission, by equalising the 
maximum possible amount of follow-up time. For both definitions, follow-up was also censored at 
date of death, if occurred. 
 
Sensitivity analyses. We conducted comparable analyses to those described earlier, but restricted 
the study population to HCV RNA-positive persons, and also compared mean cumulative length 
of stay across HCV RNA status categories (see Supporting Information, Tables S2 and S3). 
 
Statistical analyses. Multifactorial Poisson regression was used to infer the patient and other 
factors (age, sex, RNA status, admission for HCC prior to first DC admission, period of first DC 
admission) associated with cumulative length of hospital stay. We define cumulative length of stay 
as the total stay in hospital (i.e., summing multiple admissions) within a patient’s follow-up period. 
We used Cox regression with robust standard errors to confirm temporal trends in admission rates 
for all admissions, and in admission rates categorised as liver-related only, controlling for 
important confounders (age, sex, risk group, prior alcohol-related admission, HCV RNA status, 
and prior HCC admission). 
 
The counting-process formulation for recurrent events was adopted for person-time analyses. All 




Patient characteristics  
A total of 1,543 HCV diagnosed persons had a first inpatient hospital admission for DC within the 
period 1996–2013, increasing 3.9-fold between 1996-98 and 2011-13 (Table 1a). Males constituted 
the majority of patients (73%), and the mean age at first DC admission was 47 years. Previous to 
their first DC admission, 56% and 4.2% had an alcohol-related admission or HCC admission, 
respectively. Seventy-seven percent of patients had tested HCV RNA-positive prior to index 
admission (85% of those whose HCV RNA status was known). As of 31 May 2014, 457 (30%) DC 
patients were not known to have died. 
 
The most prevalent DC diagnosis code at index DC admission, over all six triennia, was ascites 
(57%), followed by chronic hepatic failure (21%). The prevalence of both ascites and alcoholic 
hepatic failure tend to increase with triennium, whereas the prevalence of bleeding varices tend to 
decrease over the study period. 
 
Temporal trends in inpatient admissions and total stay 
Between 1996 and 2013, the total number of inpatient admissions among the study population of 
HCV diagnosed patients with DC increased 16-fold, from 112 to 1791, and the annual total 
inpatient hospital stay also increased 11-fold over the same period, from 719 days in 1996 to 8045 
in 2013 (Fig. 1), reflecting rising DC patient numbers. The distribution over admission category in 




Aggregating over all six triennia, there were 10,179 inpatient admissions in total, for an overall 
admission rate of 7.9 admissions per person-year (Table 1b). When computed separately by 
triennium of first DC admission, there was an apparent increasing trend in admission rate from 
1999–2001 (7.4 per person-year) to 2011–2013 (9.6 per person-year). Cox regression analysis, 
adjusting for confounders, confirmed this increasing trend for all admission categories (HR for year 
of first DC admission=1.024, 95% CI: 1.019–1.029) and for liver-related admissions only (HR for 
year=1.023, 95% CI: 1.017–1.029) (see Supporting Information, Table S4). The median length of stay 
per admission was constant at 3 days from the beginning of the study period, dropping to 2 days 
in the most recent triennium. 
 
In sensitivity analysis of the study population restricted to chronically-infected (HCV RNA-
positive) individuals, very similar temporal trends in admission rates were apparent (Supporting 
Information, Table S3). 
 
Length of stay since first DC admission 
Considering all admissions as a function of time since index DC admission, there was a rapid drop 
off in the proportion of patients in hospital, with time. The mean cumulative length of stay per 
patient stratified by admission code category, according to three censored follow-up period 
definitions, is shown in Table 2. The study population for this analysis consisted of 1312 patients 
with a first admission between 1 January 1996 and 31 May 2012. Considering 2 years of follow-up 
starting with the index admission, the mean cumulative length of stay per patient was 43 days, 
with averages of 39 and 5 days for liver- and non-liver related only coded admissions, respectively. 
Shorter (i.e., 1 year and 6 months) censoring thresholds gave disproportionately lower average 
cumulative lengths of stay, illustrating the greater chance of subsequent hospitalisation following 
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index admission. Among all admissions, 79% and 60% of the mean cumulative stay calculated over 
the first 2 years of follow-up occurred within the first year and the initial 6 months, respectively.  
 
Patient factors associated with cumulative length of inpatient stay were determined via Poisson 
regression (Table 3). Patients aged 60+ years had longer total stay (RR=1.11, 95% CI: 1.08–1.14), as 
did patients with one or more alcohol-related admissions before first DC admission (RR=1.21, 95% 
CI: 1.19–1.23), but having ever been admitted for HCC prior to first DC admission (RR=0.68, 95% 
CI: 0.64–0.71) or if first DC admission was for bleeding varices (RR=0.83, 95% CI: 0.80–0.85) was 
associated with a shorter stay. 
 
The majority of the inpatient burden fell within the beginning of follow-up, paralleling the 
survival function. Among the DC patient cohort with a minimum observation time of 5 years, of 
the 926 patients alive at time zero, only 216 were alive five years later. The first follow-up year 
accounted for 30,884 inpatient days (60% of total stay over 5 years) of which the vast majority of 
the burden (84.3%) was due to liver-related admissions (Supporting Information, Table S5). 
 
In sensitivity analysis comparing RNA-positive and RNA-negative subgroups, there was little 
difference in cumulative stay per patient considering admissions for any reason, except that RNA-
negative patients had a slightly higher average cumulative stay for the category other liver-related 
compared with RNA-positive DC patients (15.5 and 13.8 days, respectively; Table S2). 
 
Proportion of admissions with liver -and non-liver related diagnoses 
Fig. 2 presents the proportion of admissions subsequent to index DC admission, according to 
broad hierarchically defined code category and by year of follow-up, aggregating all DC patients 
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(see Supporting Information, Figs. S2 and S3 for comparable plots, but showing liver-related and 
non-liver related only admissions with finer-grained subcategories). Approximately 50% of all 
admissions within the first year following index admission were classified as HCC or DC; this 
proportion tended to decrease over year of follow-up.  
 
Among the subcategories of non-liver related admissions, there was no observable pattern by year 
of follow-up (Fig. S3a), but the proportion of admissions classified as injuries and poisonings was 
highest for the youngest age-group, and the proportion of admissions in the category circulatory 
and respiratory tended to increase with older age-group (Fig. S3b). 
 
DISCUSSION 
The burden of hospital usage in our DC patient population is high; our DC patients spent on 
average 43 days in hospital (Table 2), assuming a follow-up period censored at 2 years following 
index DC admission. The inpatient hospital burden is greatest within the year immediately after 
admission for the first decompensation event, and diminishes thereafter (Fig. S1,Table S5). We 
observed an overall inpatient/daycase admission rate of 7.3 per person-year (12.8 admissions per 
person-year considering the first 6 months of follow-up).  
 
Our estimates of the per-patient mean hospital stay varied by period of follow-up (Table S5), 
dropping from 33.4 days in the first year to 10.7 days in the fifth year. This finding suggests that 
using a single annualised value, such as that reported for DC patients (21 days) by Wright et al.,15 
in cost-effectiveness analyses (CEA) could be problematic. As the Markov modelling approaches 
underlying CEA typically use yearly time steps, applying a single annualised length of stay to all 
simulated DC patient-years in the model, when the length of stay differs according to duration 
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within the DC stage, may give misleading estimates of the total hospital burden borne by this 
patient group, and therefore could potentially influence the conclusions of the CEA. Comparison 
of these values is not straightforward, as Wright et al.’s values excluded patients with <40 days 
observation time, and were for 'hepatitis C-related' resource use only. Although the difference 
between estimates may be partly due to sample size, we believe that these difference in 
methodology are the most relevant. 
  
There was a clear increasing trend in admission rate over triennium from 1999-2001; this reached 
9.6 admissions per person-year in patients with first DC admission in 2011-2013. This trend 
probably reflects ageing of the HCV-diagnosed population, or possibly increased willingness over 
time to accept medical interventions. Related to this finding, there were age-group differences with 
respect to severity – the 60+ year age-group had the highest proportion of HCC-classified 
admissions, consistent with the oldest living patients having the longest duration of chronic 
infection. 
 
We observed an approximate monotonic increase in annual total hospital stay over the study 
period, consistent with a rapid rise in the cumulative number of living DC patients over the period 
1994-2013.3 The decreasing trend in mean stay for admissions for HCC or DC over the study 
period may indicate improved management of patients with the most severe disease, but also 
could reflect changing practice in outpatient vs. inpatient treatment, but we have no data to 
address this. The apparent decreasing trend across triennium in the prevalence of bleeding varices 
at first DC admission (Table 1) may be a consequence of earlier detection via screening initiatives 
and consequent treatment (P. Hayes, pers. comm.)  
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We note that focussing on DC/HCC admissions only does not reflect the extensive hospital burden 
borne by this patient group. Although admissions for hepatic failure and ascites/varices led to a 
mean cumulative inpatient stay of 11 and 13 days, respectively (Table 2), the mean cumulative 
length of stay for liver-related diagnoses outwith the defined DC codeset was comparable, at 14 
days. The other liver-related subcategory includes ‘Alcoholic liver disease, unspecified’ (K70.9) – the 
most frequently occurring code in this subcategory – suggesting that the high prevalence of 
current or historical problem alcohol use in this DC patient population contributes a significant 
portion of the hospitalisation burden. Furthermore, separation of RNA-positive and RNA-negative 
patients indicated that average cumulative stay with respect to the other liver-related category was 
approximately 12% longer for the latter subgroup (Table S2). This difference is consistent with a 
higher likelihood that progression to DC in the RNA-negative subgroup was driven more by 
alcohol then HCV infection. 
 
Limitations of our study include possible misclassification error in the coding of hospital 
admissions. We also lacked information on clinical disease stage or on liver transplantation. The 
apparent greatly improved disease course in a proportion of our DC patients (as indicated by no 
further inpatient admissions after an initial cluster of DC and other liver-related admissions) could 
indicate reversal of severe disease, potentially via successful transplantation. However, relatively 
few liver transplantations took place during the study period, and transplant patients in Scotland 
can have an inpatient record generated with a code indicating prior liver transplantation; this 
occurred for only a small proportion.3 
 
We considered the first 2 years following first DC admission to usefully represent the typical DC 
patient’s inpatient history. All censoring thresholds are arbitrary, but for estimation of the burden 
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of hospital usage in DC patients, using this threshold to interpret the results represents an 
arguably reasonable compromise between capturing the excess morbidity in this population and 
discounting ´background morbidity´. 
 
In summary, we report a substantial rising burden of inpatient hospital usage among Scottish 
HCV-diagnosed patients with decompensated liver disease. The average length of hospital stay 
was clearly dependent on follow-up period, with the highest burden observed in the initial year 
after developing DC. During our study period there were very few DC patients who would have 
been initiated on direct-acting antiviral (DAA) treatment; this study should be repeated once 
sufficient follow-up is available for the expected increasing numbers of patients who will clear the 
virus following DAA treatment. Nevertheless, the present findings will be eminently useful for 
evaluations of the impact of interferon-free antiviral therapy in preventing DC and associated 
morbidity (as indicated by inpatient hospital stay), and in potentially reducing liver and non-liver 
related morbidity among successfully treated DC patients, for whom current guidelines 
recommend urgent treatment.26 
 
ACKNOWLEDGEMENTS 
We thank the Hepatitis C Clinical Database Monitoring committee, clinical data entry staff and the 
following virologists for their support with the HCV diagnosis database: Dr Sheila Burns (East of 
Scotland Specialist Virology Centre, Royal Infirmary of Edinburgh), Dr Sheila Cameron (West of 
Scotland Specialist Virology Centre, Gartnavel General Hospital), Dr Paul McIntyre (Department 
of Medical Microbiology, Ninewells Hospital and Medical School) and Dr Pamela Molyneaux 
(Department of Medical Microbiology, University Medical School, Foresterhill).  
18 
REFERENCES 
(1) D'Amico G, Pasta L, Morabito A, et al. Competing risks and prognostic stages of cirrhosis: a 25-
year inception cohort study of 494 patients. Aliment Pharmacol Ther 2014;39:1180-1193. 
(2) Fattovich G, Pantalena M, Zagni I, et al. Effect of hepatitis B and C virus infections on the 
natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 
2002;97:2886-2895. 
(3) McDonald S, Innes H, Aspinall E, et al. Prognosis of 1,169 hepatitis C chronically-infected 
patients with decompensated cirrhosis in the pre-direct acting antiviral era. J Viral Hepat 
2017;24:295-303. 
(4) European Association for the Study of the Liver. EASL Recommendations on Treatment of 
Hepatitis C 2016. J Hepatol 2017;66:153-194. 
(5) Cheung MC, Walker AJ, Hudson BE, et al. Outcomes after successful direct-acting antiviral 
therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;65:741-
747. 
(6) Foster GR, Irving WL, Cheung MC, et al. Impact of direct acting antiviral therapy in patients 
with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;64:1224-1231. 
(7) el-Serag HB, Kunik M, Richardson P, Rabeneck L. Psychiatric disorders among veterans with 
hepatitis C infection. Gastroenterology 2002;123:476-482. 
(8) Innes H, McDonald S, Hayes P, et al. Mortality in hepatitis C patients who achieve a sustained 
viral response compared to the general population. J Hepatol 2017;66:19-27. 
(9) Petta S, Maida M, Macaluso FS, et al. Hepatitis C virus infection is associated with increased 
19 
cardiovascular mortality: a meta-analysis of observational studies. Gastroenterology 2016;150:145-
155. 
(10) Liu S, Cipriano LE, Holodniy M, Goldhaber-Fiebert JD. Cost-effectiveness analysis of risk-
factor guided and birth-cohort screening for chronic hepatitis C infection in the United States. 
PLoS One 2013;8:e58975. 
(11) Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V. Direct economic burden of chronic 
hepatitis C virus in a United States managed care population. J Clin Gastroenterol 2011;45:e17-24. 
(12) McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI. All-cause and 
incremental per patient per year cost associated with chronic hepatitis C virus and associated liver 
complications in the United States: a managed care perspective. J Manag Care Pharm 2011;17:531-
546. 
(13) Deuffic-Burban S, Schwarzinger M, Obach D, et al. Should we await IFN-free regimens to treat 
HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141). J Hepatol 
2014;61:7-14. 
(14) van Santen DK, de Vos AS, Matser A, et al. Cost-effectiveness of hepatitis C treatment for 
people who inject drugs and the impact of the type of epidemic: Extrapolating from Amsterdam, 
the Netherlands. PLoS One 2016;11:e0163488. 
(15) Wright M, Grieve R, Roberts J, Main J, Thomas HC, UK Mild Hepatitis C Trial Investigators. 
Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and 
economic evaluation. Health Technol Assess 2006;10:1-113, iii. 
(16) Wright M, Forton D, Main J, et al. Treatment of histologically mild hepatitis C virus infection 
with interferon and ribavirin: a multicentre randomized controlled trial. J Viral Hepat 2005;12:58-
20 
66. 
(17) Martin NK, Vickerman P, Dore GJ, et al. Prioritization of HCV treatment in the direct-acting 
antiviral era: An economic evaluation. J Hepatol 2016;65:17-25. 
(18) Scott N, Iser DM, Thompson AJ, Doyle JS, Hellard ME. Cost-effectiveness of treating chronic 
hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia. J 
Gastroenterol Hepatol 2016;31:872-882. 
(19) Kendrick S, Clarke J. The Scottish Record Linkage System. Health Bulletin (Edinburgh) 
1993;51:72-79. 
(20) Shaw L, Taylor A, Roy K, et al. Establishment of a database of diagnosed HCV-infected 
persons in Scotland. Commun Dis Public Health 2003;6:305-310. 
(21) Health Protection Scotland. Surveillance of known hepatitis C antibody positive cases in 
Scotland: Results to 31 December 2013. HPS Weekly Report: Health Protection Scotland 
2014;18(2011/18):243-249. 
(22) Costella A, Goldberg D, Harris H, et al. Hepatitis C in the UK 2015 Report. London: Public 
Health England; 2015. 
(23) Innes HA, McDonald SA, Dillon JF, et al. Toward a more complete understanding of the 
association between a hepatitis C sustained viral response and cause-specific outcomes. 
Hepatology 2015;62:355-364. 
(24) Ioannou GN, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. The prevalence of cirrhosis 
and hepatocellular carcinoma in patients with human immunodeficiency virus infection. 
Hepatology 2013;57:249-257. 
21 
(25) R Development Core Team. R: A language and environment for statistical computing. Vienna, 
Austria; 2014. 
(26) European Association for Study of Liver. EASL Clinical Practice Guidelines: management of 
hepatitis C virus infection. J Hepatol 2014;60:392-420. 
  
22 
Table 1. (a) Characteristics of, and (b) total inpatient admissions among HCV-diagnosed patients with 
decompensated cirrhosis (DC), by triennium of first DC admission; study population is defined as persons 
with a first hospital admission with mention of DC within the period 1996-2013 (n = 1,543). 
 Period of first DC admission 
 1996-1998 1999-2001 2002-2004 2005-2007 2008-2010 2011-2013 Total 
(a) Patient characteristics  
N patients 107 164 217 279 363 413 1543 
Males, n (%) 78 (72.9) 119 (72.6) 164 (75.6) 203 (72.8) 263 (72.5) 302 (73.1) 1129 (73.2) 
Mean age in 
  years (SD) 46.7 (14.8) 48.2 (13.9) 46.7 (12.1) 45.2 (10.1) 47.2 (10.8) 48.2 (10.3) 47.1 
(11.5) 
Risk group 
   PWID, n (%) 41 (38.3) 49 (29.9) 101 (46.5) 156 (55.9) 164 (45.2) 199 (48.2) 710 (46.0) 
   NonPWID, n (%) 12 (11.2) 20 (12.2) 16 (7.4) 21 (7.5) 30 (8.3) 19 (4.6) 118 (7.6) 
   NK, n (%) 54 (50.5) 95 (57.9) 100 (46.1) 102 (36.6) 169 (46.6) 195 (47.2) 715 (46.3) 
Prevalence of DC complications at first DC admission (%) 
  Ascites 43 48 57 59 61 61 57.4   
  Bleeding varices 22 21 14 13   12    12 13.9 
  Hepatic failure, 
    incl. enceph. 29 24 20 18 19 20 20.5 
  Alcoholic hepatic  
    failure   9 12 12 14 12 14 12.5 
   Hepatorenal  
     syndrome 4 3 7 3 4 2 3.5 
Prior alcohol-related  
  admission (%) 45 52 53 57 63 56 56.3 
Prior admission 
  for HCC (%) 6 4 2 3 4 7 4.2 
HCV RNA status at first DC admission (%) 
   RNA +ve 47.7 61.6 75.6 81.7 82.1 84.5 77.2 
   RNA –ve 6.5 11.0 13.8 13.6 13.5 12.6 12.6 
   NK 45.8 27.4 10.6 4.7 4.4 2.9 10.2 
Dead as of 




(b) Inpatient admissions  
N patients 107 164 217 279 363 413 1543 
Total admissions* 532 807 1332 1887 2565 3056 10179 
Person-years* 72 136 198 259 308 319 1292 
Admissions per  
 person-year* 7.42 5.92 6.74 7.30 8.32 9.57 7.88 
Median stay per 
   admission (days) [IQR] 3 [1-9] 3 [1-9] 3 [1-8] 3 [1-7] 3 [1-7] 2 [1-5] 3 [1-7] 
 
Note: PWID = people who inject drugs; NK = not known; diagnosis codes: ascites = R18; bleeding varices = 
I85.0, I98.3; hepatic failure = K72.1, K72.9; alcoholic hepatic failure = K70.4; hepatorenal syndrome = K76.7; 
IQR = interquartile range. Median length of stay is per admission. 
* Based on an allotted additional 5 months of follow-up following each 3-year period, to ensure 




Table 2. Inpatient hospital usage by HCV-diagnosed patients first admitted for decompensated 
cirrhosis (DC) in the period 1 January 1996 to 31 May 2012 (n = 1312), according to different follow-
up periods (entire, first 2 years, first year, and first 6 months). All hospital admissions during 
patient’s entire history until censoring boundary, starting with first DC admission, are presented, 
and are additionally stratified by hierarchically-defined diagnosis code category. 
 
 Entire period First 2 years First year First 6 months 
Total admissions 13863 9102 6786 4823 
Person-years 3036 1247 708 376 
Admissions per  
  person-year 4.57 7.30 9.59 12.81 
Median  length of stay 
   per admission (days) [IQR] 2 [1-6] 3 [1-7] 3 [1-7] 3 [1-8]  
Mean cumulative length of stay per patient (days) according to admission code category: 
All 59.8 43.3 34.2 26.1 
  Liver-related 50.6 38.8 31.1 24.0 
    HCC 22.3 1.6 1.4 1.1 
    DC - hepatic failure 24.9 10.8 9.1 7.3 
    DC - ascites/varices 22.1 12.7 11.4 10.0 
    Other liver-related 33.4 13.6 9.3 5.6 
  Non-liver related only 20.2 4.5 3.1 2.1 
 
Note: IQR = interquartile range. Median length of stay is per admission; mean cumulative length of stay is 
total stay (summing multiple admissions) within follow-up period summed over all patients, then divided 




Table 3. Results of multivariate Poisson regression analysis of patient and other factors associated 
with cumulative length of stay, among HCV-diagnosed patients first admitted for decompensated 
cirrhosis in period 1996–2013. Follow-up is censored at 2 years following first DC admission. 
 
 Adjusted rate ratio     95% confidence interval 
Male sex 0.81 0.80-0.83 
Age at first DC admission 
   <40 years 0.94 0.92-0.96 
   40-49 years Ref. 
   50-59 years 1.01 0.99-1.04 
   60+ years 1.11 1.08-1.14 
Risk group 
   PWID Ref. 
   NonPWID, 1.01 0.97-1.04 
   NK 1.00 0.98-1.02 
Prior admission for HCC 0.68 0.64-0.71 
Prior alcohol-related admission 1.21 1.19-1.23 
HCV RNA status at first DC admission 
   RNA +ve Ref. 
   RNA –ve 1.00 0.98-1.03 
   NK 1.00 0.97-1.03 
Hierarchically-defined diagnosis code category, first DC admission 
   Hepatic failure Ref. 
   Ascites 1.12 1.10-1.15 
   Bleeding varices 0.83 0.80-0.85 
Period of first DC admission 
   1996-1998 0.96 0.92-1.00 
   1999-2001 0.94 0.91-0.97 
   2002-2004 1.17 1.13-1.21 
   2005-2007 1.12 1.09-1.15 
   2008-2010 1.06 1.03-1.09 





Fig. 1. Burden of inpatient hospital usage among HCV-diagnosed DC patients in the period 
1996-2013. Total stay in hospital is plotted by calendar year and stratified by hierarchically-defined 
broad diagnosis code category. The table below the x-axis indicate the annual total number of 
admissions.  
 
Fig. 2. Distribution over inpatient admission diagnosis category among HCV-diagnosed 
persons (first admitted with DC in period 1996-2013). Distribution of all recorded hospital 
admissions subsequent to patient’s first DC admission among the set of three hierarchically-
defined diagnosis code categories is plotted by time since first DC admission. The table below the 
x-axis indicate annual total numbers of admissions contributing to each stacked bar. The x-axis 
label ‘0’ relates to [0,1); ‘1’ relates to [1,2), etc. 
 
